asa guidelines for glp-1 drugs 2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations on the peri-procedural use of GLP-1/GIP receptor agonists GLP-1 drugs and aspiration risk

Studies were divided between pre-clinical and mechanistic evidence, and clinical evidence

Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ

However, rare and serious complications can occur, such as acute pancreatitis (indicated by severe, persistent stomach pain that radiates to your back)

Clinicians should judiciously balance potential benefits against risks when considering the use of these agents in pregnant patients and, where feasible, engage in thorough preconception counseling.225,226 Future research should prioritize the evaluation of long-term safety outcomes during pregnancy and potential fetal effects to inform safer clinical practices

Is insurance coverage a factor